Iovance Biotherapeutics Inc Stock Nasdaq
Equities
US53619R1023
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 153M | Sales 2025 * | 428M | Capitalization | 2.99B |
---|---|---|---|---|---|
Net income 2024 * | -356M | Net income 2025 * | -199M | EV / Sales 2024 * | 19.1 x |
Net cash position 2024 * | 72.44M | Net cash position 2025 * | 144M | EV / Sales 2025 * | 6.64 x |
P/E ratio 2024 * |
-7.99
x | P/E ratio 2025 * |
-15.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.59% |
Latest transcript on Iovance Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 16-09-29 |
Director of Finance/CFO | 51 | 20-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Director/Board Member | 56 | 16-06-06 | |
Michael Weiser
BRD | Director/Board Member | 61 | 18-03-14 |
1st Jan change | Capi. | |
---|---|---|
-29.78% | 9.84B | |
-2.96% | 3.15B | |
-14.73% | 2.15B | |
-15.05% | 1.8B | |
+69.62% | 1.49B | |
+23.08% | 770M | |
-2.84% | 762M | |
-24.08% | 575M | |
+5.37% | 308M |